This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Study Type
OBSERVATIONAL
Enrollment
2,000
In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
NOT_YET_RECRUITINGThe First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Hefei, Anhui, China
RECRUITINGThe Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
RECRUITINGOverall Survival
The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.
Time frame: Up to 10 years
Progression-Free Survival
Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.
Time frame: Up to 10 years
Treatment-Related Adverse Events
The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.
Time frame: Within 90 days post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.